Pilot neoadjuvant trial in breast cancer with combination of ABI-007 (Abraxane) [paclitaxel] and GW572016 (lapatinib).
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 02 Feb 2018 Planned End Date changed from 1 Aug 2015 to 1 Aug 2020.
- 10 Jun 2017 Biomarkers information updated
- 24 Sep 2014 Planned End Date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.